The Somascan® Assay: biomarker discovery to delivery
Watch the webinar now
ABSTRACT
The SomaScan® Assay is a proteomic platform that uses single-stranded DNA engineered with aromatic hydrocarbon side chains for binding to protein targets. The SomaScan® Assay has been used to identify signals as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.
Sheri K. Wilcox, Ph.D
Scientific Liaison and Technical Services, SomaLogic Inc
Sheri K. Wilcox is Senior Director, Scientific Liaison and Technical Services, at SomaLogic, Inc. in Boulder, Colorado. She received her B.S. in Chemistry from Vanderbilt University in Nashville, Tennessee, in 1993 and her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California, in 1999. She completed two years of post-doctoral studies at Pharmacia and Upjohn in Kalamazoo, Michigan, and then joined SomaLogic, Inc. in 2001, where she has been contributing to the generation and utility of novel protein affinity reagents based on Slow-Off rate Modified Aptamers (SOMAmer® reagents) for over 19 years.
More webinars
WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
WebinarProteomics for precision neuroscience: the power of protein analysis
This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.